AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXVertex Pharmaceuticals said net product revenues in Q1 2025 increased to $2.8 billion compared with $2.7 billion in Q1 2024, citing the continued performance of TRIKAFTA/KAFTRIO and initial contributions from ALYFTREK as factors.
Key points
AI summaryVertex Pharmaceuticals said net product revenues in Q1 2025 increased to $2.8 billion compared with $2.7 billion in Q1 2024, citing the continued performance of TRIKAFTA/KAFTRIO and initial contributions from ALYFTREK as factors.
The company said total R&D, acquired in-process research and development, and SG&A expenses in Q1 2025 increased to $1.4 billion compared with $1.2 billion in the prior-year period. It also said that following its decision to discontinue development of VX-264, it recorded a full intangible asset impairment charge of $379.0 million.
Vertex Pharmaceuticals said JOURNAVX received FDA approval in January 2025 and that since becoming available in early March, more than 20,000 prescriptions have been written and filled across hospital and retail settings. In Q1 2025, CASGEVY revenues were $14.2 million.
The company said cash provided by operating activities in Q1 2025 was $818.9 million and cash used in financing activities was $680.4 million. As of March 31, 2025, total cash, cash equivalents and marketable securities were $11.4 billion.
Key figures
Quarter ended March 31, 2025
- Revenue
- $2.8B
- Operating income
- $630M
- Net income
- $646M
- EPS
- $2.49
- Operating cash flow
- $819M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2025 Net Product Revenues $2.8 billion
Vertex Pharmaceuticals said net product revenues in Q1 2025 increased to $2.8 billion compared with $2.7 billion in Q1 2024, citing the continued performance of TRIKAFTA/KAFTRIO and initial contributions from ALYFTREK as factors.
Source · Based on the MD&A text of the filing
Q1 R&D, Acquired In-Process Research and Development, SG&A Expenses and VX-264 Impairment Charge
The company said total R&D, acquired in-process research and development, and SG&A expenses in Q1 2025 increased to $1.4 billion compared with $1.2 billion in the prior-year period. It also said that following its decision to discontinue development of VX-264, it recorded a full intangible asset impairment charge of $379.0 million.
Source · Based on the MD&A text of the filing
JOURNAVX Launch and CASGEVY Revenues
Vertex Pharmaceuticals said JOURNAVX received FDA approval in January 2025 and that since becoming available in early March, more than 20,000 prescriptions have been written and filled across hospital and retail settings. In Q1 2025, CASGEVY revenues were $14.2 million.
Source · Based on the MD&A text of the filing
Q1 Cash Flows and Cash and Equivalents Balance
The company said cash provided by operating activities in Q1 2025 was $818.9 million and cash used in financing activities was $680.4 million. As of March 31, 2025, total cash, cash equivalents and marketable securities were $11.4 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…